A Phase 2 interventional study of Letermovir 240 mg Oral Tablet in Infections, Cytomegalovirus, sponsored by Maimónides Biomedical Research Institute of Córdoba. Not yet recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-28.
Sponsored by Maimónides Biomedical Research Institute of Córdoba · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing letermovir in Cytomegalovirus Infections — 7 open to participants now, 8 under way, 3 of them phase 3. letermovir · Cytomegalovirus Infections.
Among the 17 studies testing letermovir in Cytomegalovirus Infections, this one is the 6th largest by planned enrollment, is one of 4 that started in 2023, is one of 4 in phase 2, and was the 11th registered.
370 studies on the registry are indexed under Cytomegalovirus Infections; 57 are open to participants now.
Browse Cytomegalovirus Infections studies →7 of the 17 studies testing letermovir in Cytomegalovirus Infections are open now, in 4 countries. Recruiting first, the newest first:
The First Affiliated Hospital of Soochow University · Sites in China
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
University of Wisconsin, Madison · Sites in United States
Ages 18+
Elisabeth Kincaide · Sites in United States
Ages 18+
Hospital do Rim e Hipertensão
Ages 18+
By country, each count listing its studies:
letermovir: first FDA approval 2017 (PREVYMIS), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 35 Cytomegalovirus Infections studies recruiting now, 20 (57%) set no upper age limit and 13 (37%) stop at 75 or younger; 19 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2019; this study’s year is marked. 4 started in 2023.
This study's planned enrollment of 90 is above the median of 64 across 240 interventional studies indexed under Cytomegalovirus Infections.
Median enrollment 80 across the 17 interventional studies. Of the 9 that completed or were terminated, 6 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 17 have an industry lead sponsor. The 10 most frequent:
Maimónides Biomedical Research Institute of Córdoba is the lead sponsor of 79 studies on the registry; 19 are open to participants now.
Maimónides Biomedical Research Institute of Córdoba has 3 studies filed under Cytomegalovirus Infections — fewer than ten, so there is no comparison to draw.
4 of the studies testing letermovir in Cytomegalovirus Infections that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06407232Phase 3University of Wisconsin, MadisonLetermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients | 2027-08 |
| NCT06334497Phase 3Assistance Publique - Hôpitaux de ParisLetermovir-based Dual Therapy for Treatment of Cytomegalovirus Infections | 2027-09 |
| NCT06066957University of PennsylvaniaOpen Label Trial of Oral Letermovir for CMV Prophylaxis in Thoracic Transplant Recipients | 2026-12-15 |
| NCT06057194Maimónides Biomedical Research Institute of CórdobaEfficacy of Letermovir in Preventing Cytomegalovirus (CMV) Infection in Lung Transplant Recipients vs. Valganciclovir. | 2027-04 |
Add all 4 to your calendar (.ics) → With an account.
Among the 17 studies testing letermovir in Cytomegalovirus Infections, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this quasi-experimental multicenter before-after cohort study, phase II study is to evaluate the efficacy of 12-month letermovir prophylaxis in lung transplant recipients (D+/R-) compared to a historical cohort of lung transplant recipients (D+/R-) who received 12 months of valganciclovir prophylaxis to prevent CMV disease."
Inclusion Criteria (prospective cohort):
Exclusion Criteria (prospective cohort):
Inclusion Criteria (retrospective cohort):
Exclusion Criteria (retrospective cohort):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
2 tablets of 240 milligrams (mg) Letermovir orally once daily. during 12 months
Drug: Letermovir 240 mg Oral Tablet
Retrospective cohort, of patients treated with Valganciclovir during 12 months
Treatment will commence as soon as subjects can receive oral medication, with a maximum timeframe of 28 days after transplantation. If patients cannot receive oral medication after transplantation, initial prophylaxis with ganciclovir per clinical practice will be allowed. Medication will be discontinued 12 months after treatment initiation.
Incidence of CMV disease/replication
CMV replication: The term 'replication' can be used to indicate evidence of multiplication and is sometimes used interchangeably with CMV infection CMV disease: It is defined as symptomatic replication or invasive disease of organs or tissues that requires treatment at the investigator's discretion."
Time frame: During 12 months after initiation of prophylaxis
Antiviral prophylaxis received:
Doses administered of Letermovir or Valganciclovir
Time frame: During 12 months after initiation of prophylaxis
Dose of non anti-viral CMV Medications: Any non-antiviral therapy received as standard of care (SoC) for the management of CMV (e.g., immunoglobulins)
Drug Dose (mg/hour)
Time frame: During 12 months after initiation of prophylaxis
Administration route of non-antiviral CMV Medications: Any non-antiviral therapy received as standard of care (SoC) for the management of CMV (e.g., immunoglobulins)
Drug Administration Route
Time frame: During 12 months after initiation of prophylaxis
Duration of treatment of non-antiviral CMV Medications: Any non-antiviral therapy received as standard of care (SoC) for the management of CMV (e.g., immunoglobulins)
Drug treatment duration (days)
Time frame: During 12 months after initiation of prophylaxis
Discontinuation of non-antiviral CMV Medications: Any non-antiviral therapy received as standard of care (SoC) for the management of CMV (e.g., immunoglobulins)
Drug Reason for Discontinuation
Time frame: During 12 months after initiation of prophylaxis
Reduction of the antiviral dose related to CMV antiviral toxicity
Number of events of reduction
Time frame: During 12 months after initiation of prophylaxis
Substitution of letermovir by intravenous ganciclovir or foscarnet IV, related to CMV antiviral toxicity
Number of substitutions
Time frame: During 12 months after initiation of prophylaxis
Dose changes of immunosuppressive therapy related to CMV antiviral toxicity
Number of changes
Time frame: During 12 months after initiation of prophylaxis
Changes of immunosuppressive therapy related to CMV antiviral toxicity
Number of changes
Time frame: During 12 months after initiation of prophylaxis
Use of granulocyte colony-stimulating factors (G-CSF).
Number of events (use)
Time frame: During 12 months after initiation of prophylaxis
Incidence of leucopenia
Incidence of leucopenia. (leucopenia will be considered if the total leukocyte count is less than 3,000/mL)
Time frame: During 12 months after initiation of prophylaxis
Incidence of neutropenia
Incidence of leucopenia. (neutropenia will be considered if the total neutrophil count is less than 1,000/mL)
Time frame: During 12 months after initiation of prophylaxis
Hospital readmission associated with CMV complication
Number of events
Time frame: During 12 months after initiation of prophylaxis
Incidence of viral, bacterial, or opportunistic fungal infections during the study follow-up period.
Number of events
Time frame: During 12 months after initiation of prophylaxis
Incidence of renal toxicity directly related to CMV antivirals.
Number of events
Time frame: During 12 months after initiation of prophylaxis
Start is estimated for Oct 2023; primary completion for Apr 2027, 42 months later.
Of 29 phase 2 interventional studies under Cytomegalovirus Infections, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 62. This study's planned 42 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Letermovir
Maimónides Biomedical Research Institute of Córdoba